AzTrials
AzTrials

Hip FracturesPhase 4NCT01850251

Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture

A Phase 4 study testing Supplement with HMB and vitamin D and Standard nutritional supplement in people with Hip Fractures, run by Hospital Clinic of Barcelona at 1 site in Spain.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether a nutritional supplement high in protein and energy, and enriched with hydroxymethylbutyrate (HMB) and vitamin D is more effective than a standard nutritional supplement high in protein and energy in improving muscle strength in elderly patients with hip fracture. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Hip Fractures
What is being tested?
Supplement with HMB and vitamin D and Standard nutritional supplement
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2 participants
Where
1 siteSpain
Study dates
Jun 2013to Mar 2015
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Patients over 65 years of age after hip fracture surgery.
  • Ability to walk before fracture.

Who cannot join

  • Chronic renal failure, defined as a glomerular filtration rate less than 60 mL/min/1.73 m2, or serum creatinine of 0.9 mg/dL in women or 1.2 mg/dL in men.
  • Following a diet with protein restriction.
  • Need for enteral or parenteral nutrition.
  • Need for medication with orexigenic or anabolic effect, or long-term corticosteroids.
  • Active neoplastic disease.
  • Cognitive impairment or major psychiatric disorder.
  • Lack of signed informed consent.
  • Any patient with inability to comply with treatment or not appropriate according to the investigator.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Hospital Clinic de Barcelona

    Barcelona, Catalonia, 08036

Other trials in Spain

About this study

Official title: Randomized Controlled, Pilot Study to Assess the Effect of a High Protein and Calorie Nutritional Supplementation Enriched Hydroxymethylbutyrate and Vitamin D on Muscle Strength and Function in Patients With Hip Fracture.

The purpose of this study is to determine whether a nutritional supplement high in protein and energy, and enriched with hydroxymethylbutyrate (HMB) and vitamin D is more effective than a standard nutritional supplement high in protein and energy in improving muscle strength in elderly patients with hip fracture.

Read the detailed description

Hip fractures are the cause of substantial morbidity and mortality in elderly people. Nine months after hip fracture, patients still have a poorer quality of life compared to control subjects matched for age and sex.

After a hip fracture, many patients fail to return to their homes and their previous state of mobility. Acute hospital costs generated by this condition are substantial, although the costs in rehabilitation and special care in long-term community are even greater.

Patients with hip fracture are most likely to be frail elderly, and they are usually malnourished when the fracture occurs. Moreover, physiological aging is accompanied by functional losses and changes in the various organs and systems, including the musculoskeletal system, in which there is a progressive reduction of muscle mass, called sarcopenia. Approximately 30% of muscle mass is lost between the fifth and eighth decades of life and the percentage of muscle loss can reach 15% per decade after 70 years of age. Having established a correlation between the loss of muscle mass and loss of strength, sarcopenia has been associated with a risk of functional disability twice in men and thrice in women.

Hydroxymethylbutyrate (HMB) is a leucine metabolite produced in small quantities (0.3-0.4 g/d). Leucine effects on muscle metabolism appear to be due, in part, to HMB. In vitro experiments have observed that HMB attenuates proteolysis processes through the inhibition of various catabolic pathways and could stimulate protein synthesis. There are some evidences that administration of HMB in the elderly results in increases in muscle strength and functionality enhancements, compared to a control group.

In elderly people, low levels of vitamin D have been associated, among others, to decreased muscle strength, falls and fractures. The elderly have an increased risk of developing vitamin D deficiency due to less sun exposure, a decrease in the absorption and changes in the metabolism of this vitamin. Because muscle weakness is a clinical feature of vitamin D deficiency, it has been postulated that its deficiency could precipitate and increase muscle weakness and functional decline in older people.

Therefore, the study raises the possibility that an intervention consisting of a high protein, high calorie oral nutritional supplement enriched with HMB and vitamin D is more effective than a standard high protein, high calorie oral nutritional supplement in improving muscle strength.

Conditions
Hip Fractures
Being tested
Supplement with HMB and vitamin D, Standard nutritional supplement
Keywords
Hip fractures, Ageing, Sarcopenia, Function
Medical subject headings
Hip Fractures, Sarcopenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supplement with HMB and vitamin DDietary supplement

    Also called Ensure Plus Advance

    High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.

  • Standard nutritional supplementDietary supplement

    Also called Ensure Plus High Protein

    High protein, high calorie nutritional supplement.

Study groups in NCT01850251
Study groupRoleWhat they receive
Supplement with HMB and vitamin DExperimentalOral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
Receives: Dietary Supplement: Supplement with HMB and vitamin D
Standard nutritional supplementActive comparatorOral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
Receives: Dietary Supplement: Standard nutritional supplement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in bilateral knee extension test as a measure of isometric muscle strength.

    Changes from baseline in the knee extension test at 8 weeks will be conducted using a dynamometer.

    Measured: Baseline and 8 weeks

Secondary outcomes (1)
  1. Change in the Timed Up & Go test as a measure of function.

    Changes from baseline in the Timed Up \& Go functional test at 8 weeks.

    Measured: Baseline and 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 May 2013 (estimated)
  2. Study startJun 2013
  3. Primary completionMar 2015
  4. Study completionMar 2015

Why it stopped: Recruiting problems.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01850251
Sponsor's protocol ID
ORTOHMB-13
Status last verified
Aug 2015
First submitted
3 May 2013
Last updated
19 Aug 2015
Results posted
No
Data monitoring committee
No

Publications

  • Fuller JC Jr, Baier S, Flakoll P, Nissen SL, Abumrad NN, Rathmacher JA. Vitamin D status affects strength gains in older adults supplemented with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and lysine: a cohort study. JPEN J Parenter Enteral Nutr. 2011 Nov;35(6):757-62. doi: 10.1177/0148607111413903. Epub 2011 Aug 1.

    PubMed 21807930

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Supplement with HMB and vitamin D and Standard nutritional supplement in people with Hip Fractures, run by Hospital Clinic of Barcelona at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 19 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Recruiting problems.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in bilateral knee extension test as a measure of isometric muscle strength. (time frame: Baseline and 8 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01850251, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in